Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentaxim + Euvax B
- Development stage
- Unknown
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Pentaxim + Euvax B refers to a combination immunization regimen consisting of two separate vaccine products developed by Sanofi Pasteur: Pentaxim (a pentavalent vaccine) and Euvax B (a recombinant hepatitis B vaccine). Pentaxim provides active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Hib). It contains diphtheria and tetanus toxoids, acellular pertussis antigens (pertussis toxoid and filamentous haemagglutinin), inactivated poliovirus types 1, 2, and 3, and Hib capsular polysaccharide conjugated to tetanus protein (PRP-T). Euvax B provides protection against hepatitis B and contains the recombinant hepatitis B surface antigen (HBsAg). In clinical research, this specific co-administration regimen is frequently utilized as a standard-of-care comparator to evaluate the safety and immunogenicity of newer, fully liquid hexavalent vaccines like Hexaxim.
- Other names
- DTaP-IPV//PRP~T + hepatitis B vaccineDTaP-IPV-Hib + Hep BDTaP-IPV//PRP~T + Hep B
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)PRNP (Cellular Prion Protein)HBsAg (Hepatitis B surface antigen)Poliovirus type 1 antigenPV3 (Sabin) (Poliovirus type 3 antigen)Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Pentaxim + Euvax B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pentaxim + Euvax B.